Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
The B7-CD28 Family Molecules
The B7-CD28 family molecules are probably the most intensively studied receptor-ligand systems in the field of immunology. This is evident from the explosive accumulation of literature, particularly in the last ten years. Recent years have witnessed rapid discoveries and characterization of new receptors and ligands in the family. These new pathways, although still in their infancy, have already brought much excitement to the field. However, until now, there has been no single volume to cover this entire area. This book was created to bring together state-of-the-art information and critical thinking from the leading investigators. This book covers significant territory of this rapidly moving field from structural biology and biochemical signalling to immunological functions and their potential applications in the treatment of human diseases. This is an excellent handbook and reference for immunologists, health professionals as well as medical students and graduate students in life science field.
CD137 Pathway: Immunology and Diseases
The most practical and clinical reasons for attempting to understand the immunology of infections and disease revolves around the CD137 and CD137/41BB receptor and ligand molecules. This book covers all aspects of CD137/4-1BB pathway research from microbiology, infectious disease, molecular biology, biochemistry, and genetics to immune responses and potential applications in the diagnosis and treatment of human diseases. This pathway is emerging as one of the most important targets for manipulation of immune responses for disease diagnosis and treatment. This book is written by the man who discovered the CD-137 and B7H1 molecules in 1999.
Innovative Research in Life Sciences
“I thoroughly enjoyed reading this book as it has taken me on a journey through time, across the globe and through multiple disciplines. Indeed, we need to be thinking about these concepts and applying them every day to do our jobs better.” Farah Magrabi, Macquarie University, Australia “The reader will find intriguing not only the title but also the content of the book. I’m also pleased that public health, and even more specifically epidemiology has an important place in this ambitious discussion.” Elena Andresen, Oregon Health & Science University, USA “This book is very well written and addresses an important topic. It presents many reasons why basic scientists/researchers sho...
Cancer Immunology and Immunotherapy
The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment.
Targeted Therapeutics in Melanoma
Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.
Molecular Approaches to Tumor Immunotherapy
The articles in this book are contributed by leading scientists working in the fields of immunology, tumor immunotherapy, and gene therapy. The book identifies the opportunities that modern immunology and molecular biology have provided for tumor therapy. Moreover, it contains critical essays that analyze the progress and obstacles of tumor immunotherapy.
Tumor-Induced Immune Suppression
This monograph, for the first time, presents a comprehensive overview of different mechanisms of immune dysfunction in cancer as well as therapeutic approaches to their correction. It discusses a number of new mechanisms that have never been discussed in a monograph before: T-cell inhibitory molecules, regulatory tolerogenic DCs, and signaling pathways in antigen-presenting cells involved in T-cell tolerance. There is now a pressing need to discuss the already described and newly emerging mechanisms to see how they can be put together in a more or less cohesive structure and how they can help to improve immune response to tumors.
Healthcare Reform in China
How efficient is the Chinese healthcare system? Milcent examines the medication market in China against the global picture of healthcare organization, and how public healthcare insurance plans have been implemented in recent years, as well as reforms to tackle hospital inefficiency. Healthcare reforms, demographic changes and an increase in wealth inequity have altered healthcare preferences, which need to be addressed. Significantly, the patient–medical staff relationship is analysed, with new proposals for different lines of communication. Milcent puts forward digital healthcare in China as a tool to solve inefficiency and rising tensions, and generate profit. Where China is leading in the digitalization of healthcare, other countries can learn important lessons. Chinese social models are also put into context with respect to current reforms and experimentation.
Innate Immune Regulation and Cancer Immunotherapy
Innate and adaptive immunity play important roles in immunosurveillance and tumor destruction. However, increasing evidence suggests that tumor-infiltrating immune cells may have a dual function: inhibiting or promoting tumor growth and progression. Although regulatory T (Treg) cells induce immune tolerance by suppressing host immune responses against self- or non self-antigens, thus playing critical roles in preventing autoimmune diseases, they might inhibit antitumor immunity and promote tumor growth. Recent studies demonstrate that elevated proportions of Treg cells are present in various types of cancers and suppress antitumor immunity. Furthermore, tumor-specific Treg cells can inhibit immune responses only when they are exposed to antigens presented by tumor cells. Therefore, Treg cells at tumor sites have detrimental effects on immunotherapy directed to cancer.
The Oncogenomics Handbook
An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.
